AI assistant
Monopar Therapeutics — Director's Dealing 2022
Oct 4, 2022
32883_dirs_2022-10-03_0eda3988-c4cc-4079-81fd-fd5aac8f5257.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-09-30
Reporting Person: Cittadine Andrew (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-09-30 | Common Stock | M | 4063 | — | Acquired | 9376 | Direct |
| 2022-09-30 | Common Stock | F | 1191 | $1.52 | Disposed | 8185 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-09-30 | Restricted Stock Units | $ | M | 4063 | Disposed | Common Stock (4063) | Direct |
Footnotes
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.